UCLPartners Board

Tuesday 22April 2014, 4:00-6:00pm

UCLPartners Boardroom

3rd Floor 170 Tottenham Court Road

MINUTES

PresentAjay Kakkar (Chair)

Dominic Dodd

Steve Field

David Fish

Dennis Gillings

Roger Jackling

Richard Murley

Cliff Prior

John Tooke

Richard Trembath

Elizabeth Chidgey

Polly McGivern

Observers:Mindy Smith

John Deanfield (for item 6)

Formal Items

  1. Apologies

Apologies for absence were received from Christine Beasley,Baroness Tessa Blackstone and Simon Gaskell

  1. Minutes from January Board
  • AGREED the minutes of the meeting held on 21 January 2014 were accepted as an accurate record with one change to the attendees list reflecting that Elizabeth Chidgeyattended the meeting.
  1. Matters Arising

3.1Governance

  • NOTED UCLPartners has evolved in the last 5 yearsleading to increased complexity and workload. Accordingly suitable programme leads who will report to the Board through the MD, have been appointed to strengthen the governance of the programmes and enable cohesion along the discovery to delivery into communities /populations continuum for research and innovation .
  • NOTED Comments were received from the Board highlighting the need for cohesion in the titles and content of the programmes particularly in overlapping areas. Performance metrics will be designed to appropriately monitor progress for each programme.

3.2Conflicts of Interest

  • NOTED Declarationsof were received from Richard Trembath and Richard Murley for the AOB tabled item on the Cancer and Cardiac reconfiguration.
  1. Managing Directors report

4.1 Report to NHSE

  • NOTEDThe report was tabled and reviewed by the board with positive feedback.
  • NOTED UCLP demonstrated that all the designated functions areworking together under a single umbrella providing maximum impact for our population which was recognised by NHSE.
  • NOTED Thebreadth and high number of objectives in our plan reflects UCLP’s aim to bring about a culture change through innovation and academic / health services working together to raise to the health challenges that exist.
  • ACTION The Informatics Strategy will be circulated to the Board for comment following the meeting.
  • NOTED The Executive will review the strategy on 12 May with Tom Lee attending. Medical Directors of each Trust have also been invited.

5. Finance and Corporate update

  • NOTED The Board approvedthe change of signatories from Julian Dixon, Sir Cyril Chantler and Janet Pressland to Lord Ajay Kakkar, Charlotte Williams and Polly McGivern with immediate effect.
  • NOTED Andrew Whalley would be leaving his post at the end of this month. Polly McGivern was approved as the new company secretary.
  • NOTED Polly McGivern will redraft the Articles of Association to reflect that the Chair should not hold a corporate role with any of the partners and the MD should not have any paid employment with any of the partners unless explicitly approved by the Board. AGREED Lord Kakkar would sign off the Articles once the change was made.

Financial position

  • NOTED The management accounts for the year were tabled and reviewed by the Board.

Medcity

  • NOTED A paper outlining the structure, membership and strategy for Medcity was tabled and reviewed.
  • AGREEDIt was agreed that UCLPartners would become a member of the company with a limited financial liability of £1.
  1. Dementia
  • NOTED Dennis Gillings provided a verbal report to the Board of the challenges facing the global population in addressing the prevention and treatment of Dementia.
  • NOTED Significant resource and the need for creative solutions working across therapeutic areas and between Industry and academia will be needed to identify new treatments.
  • NOTED The Mayor’s Office is supportive of aproposal for a dedicated dementia research institute in London.
  • NOTED Dennis Gillings will chair the World Dementia Council
  • AGREED The Board endorsed supportfor the proposed Dementia Research Institute linking nationally and internationally as a collaborative enabling resource.
  1. AOB: Cancer and Cardiac (tabled)
  • NOTED Theproposed cancer and cardiac case for change has beensupported byUCLPduring the last 2 years. There is significant clinical support from across the partnership, and a constructive dialogue to address outstanding concerns.
  • NOTEDAppropriate financial contributions to enable delivery of the changes, if approved by commissioners, would be required from NHSEL, providers, CCGs and UCLPartners.
  • AGREED The Board approved UCLP’s own expected financial contribution(£2m) to the cancer / cardiac reconfiguration.